Literature DB >> 12616846

Antipsychotic medication coprescribing in a large state hospital system.

Ari B Jaffe1, Jerome Levine.   

Abstract

PURPOSE: To systematically characterize antipsychotic medication coprescribing ('polypharmacy') in a large state hospital system.
METHODS: All antipsychotic prescriptions written for all adult in-patients (N = 8212) in New York state-run civil facilities for the year 1999 were identified using the Integrated Research Database (IRDB) created by the Information Systems Division of the Nathan Kline Institute for Psychiatric Research. Antipsychotics were considered to be intentionally coprescribed only when both were prescribed for an overlapping period of 28 days.
RESULTS: Coprescribing of typical, atypical, and depot antipsychotics comprised 31% of antipsychotic prescribing episodes. Medications were usually coprescribed with medications from outside their own antipsychotic class. Patient factors, such as age, diagnosis, and history of prior hospitalization, affected coprescribing rates (p < 0.001 for all indicated variables). Atypical antipsychotic medications were less likely to be given with another antipsychotic than were oral or depot typical medications.
CONCLUSIONS: Coprescribing of antipsychotic drugs is a common practice in the New York State hospital system. The analysis of large clinical databases can yield valuable information about the kinds of complex pharmacotherapy regimens actually utilized in the treatment of the most severely ill patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12616846     DOI: 10.1002/pds.783

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  26 in total

1.  Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia.

Authors:  Kang Sim; Alex Su; Senta Fujii; Shu-Yu Yang; Mian-Yoon Chong; Gabor S Ungvari; Tianmei Si; Eun K Chung; Hin-Yeung Tsang; Yiong H Chan; Stephan Heckers; Naotaka Shinfuku; Chay H Tan
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

2.  Polypharmacy of schizophrenia.

Authors:  Peter Dussias; Amir H Kalali; Leslie Citrome
Journal:  Psychiatry (Edgmont)       Date:  2010-08

3.  Does antipsychotic polypharmacy increase the risk for metabolic syndrome?

Authors:  Christoph U Correll; Anne M Frederickson; John M Kane; Peter Manu
Journal:  Schizophr Res       Date:  2006-10-27       Impact factor: 4.939

Review 4.  Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009.

Authors:  Juan A Gallego; John Bonetti; Jianping Zhang; John M Kane; Christoph U Correll
Journal:  Schizophr Res       Date:  2012-04-24       Impact factor: 4.939

5.  "Stat" medication administration predicts hospital discharge.

Authors:  Ari Jaffe; Jerome Levine; Leslie Citrome
Journal:  Psychiatr Q       Date:  2009-03-14

6.  Trends in combination antipsychotic use among persons with commercial insurance: a data snapshot.

Authors:  Leslie Citrome; Zhenchao Guo; Iftekhar Kalsekar; Robert A Forbes; Tony Hebden
Journal:  Innov Clin Neurosci       Date:  2012-03

Review 7.  A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Authors:  William G Honer; Ric M Procyshyn; Eric Y H Chen; G William MacEwan; Alasdair M Barr
Journal:  J Psychiatry Neurosci       Date:  2009-11       Impact factor: 6.186

8.  Antipsychotic Polypharmacy.

Authors:  Adriana Foster; Jordanne King
Journal:  Focus (Am Psychiatr Publ)       Date:  2020-11-05

9.  Description of long-term polypharmacy among schizophrenia outpatients.

Authors:  Jaana T Suokas; Jaana M Suvisaari; Jari Haukka; Pasi Korhonen; Jari Tiihonen
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-09-25       Impact factor: 4.328

10.  Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales.

Authors:  Taishiro Kishimoto; Koichiro Watanabe; Hiroyuki Uchida; Masaru Mimura; John M Kane; Christoph U Correll
Journal:  Psychiatry Res       Date:  2013-04-18       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.